We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.87B
AUM Growth
+$407M
Cap. Flow
+$334M
Cap. Flow %
17.86%
Top 10 Hldgs %
60.38%
Holding
58
New
8
Increased
29
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$105M
2
STOK icon
Stoke Therapeutics
STOK
+$90.1M
3
MIST icon
Milestone Pharmaceuticals
MIST
+$72.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$32.3M
5
ILMN icon
Illumina
ILMN
+$26.6M

Top Sells

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$42.3M
2
SIBN icon
SI-BONE Inc
SIBN
+$23.9M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$20.4M
4
WVE icon
Wave Life Sciences
WVE
+$17M
5
ARWR icon
Arrowhead Research
ARWR
+$8.95M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$249M 13.29%
16,587,491
+550,005
+3% +$9.6M
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$36.3B
$159M 8.52%
2,198,094
+1,362,221
+163% +$105M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$141M 7.54%
3,137,361
+623,090
+25% +$24.6M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$96.9M 5.18%
6,152,103
-70,933
-1% -$965K
STOK icon
5
Stoke Therapeutics
STOK
$1.82B
$92.6M 4.94%
+3,355,466
New +$90.1M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.66B
$91.8M 4.9%
604,236
+266,037
+79% +$32.3M
MIST icon
7
Milestone Pharmaceuticals
MIST
$144M
$91M 4.86%
+3,521,856
New +$72.6M
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
$75.1M 4.01%
632,035
+6,351
+1% +$526K
BMY icon
9
Bristol-Myers Squibb
BMY
$127B
$70.8M 3.78%
1,561,918
+36,454
+2% +$1.7M
AXNX
10
DELISTED
Axonics, Inc. Common Stock
AXNX
$62.9M 3.36%
1,534,605
+10,575
+0.7% +$297K
MASI
11
DELISTED
Masimo
MASI
$55.4M 2.96%
372,258
+8,689
+2% +$1.19M
VCEL icon
12
Vericel Corp
VCEL
$2.3B
$49.2M 2.63%
2,606,771
+118,849
+5% +$2.03M
ESTA icon
13
Establishment Labs
ESTA
$2.72B
$41.4M 2.21%
1,883,180
+557,641
+42% +$13.3M
QTTB icon
14
Q32 Bio
QTTB
$450M
$40.2M 2.15%
114,163
+17,679
+18% +$6.95M
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
$37.2M 1.98%
13,864,383
+115,000
+0.8% +$340K
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$36.3M 1.94%
723,455
+16,885
+2% +$822K
PRQR icon
17
ProQR Therapeutics
PRQR
$243M
$33.9M 1.81%
3,722,950
– –
TBIO
18
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$30.8M 1.65%
2,439,250
+1,086,280
+80% +$11.5M
AGEN
19
Agenus
AGEN
$249M
$30.3M 1.62%
513,791
+10,241
+2% +$559K
ILMN icon
20
Illumina
ILMN
$29.4B
$30.2M 1.61%
+84,296
New +$26.6M
ARWR icon
21
Arrowhead Research
ARWR
$12.1B
$29.7M 1.59%
1,120,346
-407,867
-27% -$8.95M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$26.3M 1.4%
255,270
-56,823
-18% -$4.42M
LAB icon
23
Standard BioTools
LAB
$326M
$25.6M 1.37%
2,077,471
+146,537
+8% +$1.87M
APYX icon
24
Apyx Medical
APYX
$165M
$22.8M 1.22%
3,399,899
+275,000
+9% +$1.49M
AXSM icon
25
Axsome Therapeutics
AXSM
$12.4B
$21.7M 1.16%
844,289
+248,654
+42% +$4.98M
1
2 3

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q2 2019 Portfolio in Review

As of Q2 2019, RTW Investments held 58 positions worth $1.87B, up 28% from $1.47B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

RTW Investments deployed $334M of net new capital in Q2 2019, opening 8 new positions and adding to 29 existing holdings. Its largest new stake was Stoke Therapeutics: 3,355,466 shares worth $92.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arrowhead Research, an estimated $8.95M trimmed.

  • RTW Investments's largest Q2 2019 buy was Stoke Therapeutics: 3,355,466 shares worth $92.6M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q2 2019, an estimated $105M increase.
  • RTW Investments's biggest Q2 2019 reduction was Arrowhead Research, cutting an estimated $8.95M.
  • RTW Investments fully exited LivaNova in Q2 2019, selling an estimated $42.3M.
  • RTW Investments's ten largest holdings make up 60% of its $1.87B portfolio in Q2 2019.
  • RTW Investments opened 8 new positions and closed 6 in Q2 2019.
  • RTW Investments's portfolio value rose 28% quarter-over-quarter to $1.87B.

Based on RTW Investments's 13F filing for Q2 2019, filed 14 Aug 2019.